Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04767009 | SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors | unknown | Phase 2 | 59 | Fudan UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT01753414 | Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC(POSTILV) | unknown | Phase 2 | 44 | Radiation Therapy Oncology GroupNETWORK | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05922345 | Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. | unknown | Phase 3 | 518 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06403111 | FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC | unknown | Phase 2 | 62 | Changzhou No.2 People's HospitalOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06733311 | A Study Developing a Non-invasive Urine-based Proteomic Model for Early Lung Cancer Detection.(UPD-LC) | unknown | — | 480 | Beijing Chao Yang HospitalOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06697990 | Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients | unknown | Phase 2 | 12 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 20, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06623786 | Cancer Patient Remote Monitoring for Timely Communication Study(CONNECT) | unknown | — | 100 | Asklepios proresearchINDUSTRY | 0 | Oct 2, 2024 | clinicaltrials |
| NCT06406166 | Lifei Xiaoji Wan in Treatment of Advanced NSCLC | unknown | N/A | 100 | Henan University of Traditional Chinese MedicineOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06215885 | Multi-omics Analysis to Characterize the Invasive Evolution of Pulmonary Subsolid Nodules | unknown | — | 220 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06590194 | PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 1 / Phase 2 | 96 | Suzhou Puhe Pharmaceutical Technology Co., LTDINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06481566 | Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial | unknown | N/A | 30 | Chongqing University Cancer HospitalOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT05007938 | Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer | unknown | Phase 2 | 30 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT05341583 | Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer | unknown | Phase 3 | 202 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT05229614 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease(ICONIC) | unknown | Phase 2 | 27 | CNAO National Center of Oncological HadrontherapyOTHER | 2 | Aug 21, 2024 | clinicaltrials |
| NCT05867303 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | unknown | Phase 1 | 48 | RemeGen Co., Ltd.INDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT05222087 | PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study(PRIME_LUNG) | unknown | Phase 1 | 40 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT05805319 | Dietary Intervention for NSCLC Patients Treated With ICI | unknown | N/A | 80 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT05748093 | Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat(OSIBOOST 2) | unknown | Phase 4 | 60 | Maastricht University Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03866499 | A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients | unknown | Phase 3 | 369 | Beta Pharma ShanghaiINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06496360 | Prediction of Mediastinal Station IV Lymph Node Metastasis in Non-small Cell Lung Cancer | unknown | — | 150 | Qilu Hospital of Shandong UniversityOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06234579 | Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)(GALILEO) | unknown | — | 108 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05801406 | From Benchmark to Surgical Activity: the Role of Endobronchial Fiducial Markers for Ground Glass Lung Nodules Resection.(Vortex_US) | unknown | — | 5 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06511661 | Prognostic Significance of the Uncertain Resection in NSCLC | unknown | — | 3,783 | Sun Yat-sen UniversityOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies(iPREDICT) | unknown | Phase 2 | 70 | ImaginAb, Inc.INDUSTRY | 6 | Jul 22, 2024 | clinicaltrials |
| NCT05987345 | Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer | unknown | N/A | 10 | Energenx Medical LTD.INDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06331455 | Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection(SUPER) | unknown | Phase 2 | 12 | Marc de PerrotOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT05837429 | Low Volume High Intensity Interval Training in Operated Lung Cancer Patients | unknown | N/A | 40 | Hacettepe UniversityOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT04712877 | Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers | unknown | — | 1,000 | Lung Cancer Mutation ConsortiumNETWORK | 1 | Jul 17, 2024 | clinicaltrials |
| NCT05183243 | GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results | unknown | Phase 1 | 68 | Suzhou Genhouse Bio Co., Ltd.OTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06503042 | A Study to Prospectively Validate Blood Markers Associated With Differences in Efficacy of Neoadjuvant Therapy for NSCLC | unknown | — | 100 | Tang-Du HospitalOTHER | 0 | Jul 16, 2024 | clinicaltrials |
| NCT01456429 | Assessment of Invasive Mediastinal Staging in cN1 Lung Cancer.(ASTER2) | unknown | N/A | 100 | Universitaire Ziekenhuizen KU LeuvenOTHER | 2 | Jul 15, 2024 | clinicaltrials |
| NCT06362980 | A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations(EGFR) | unknown | Phase 1 | 20 | National Cancer Center, ChinaOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT05244213 | Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC(NEOTIDE) | unknown | Phase 2 | 35 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06485557 | A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC | unknown | Phase 3 | 90 | Tang-Du HospitalOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT04807114 | A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC | unknown | — | 70 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06479005 | ETERNALS: Remote Monitoring in Lung Cancer Patients(ETERNALS) | unknown | N/A | 50 | Ziekenhuis Oost-LimburgOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06118229 | A Study to Explore the Role and Impact of Wearable Smart Devices in Perioperative NSCLC Patients | unknown | — | 300 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06479759 | LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer(ACCLAIM) | unknown | Phase 2 | 50 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT04432857 | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | unknown | Phase 1 | 63 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 2 | Jun 27, 2024 | clinicaltrials |
| NCT05816499 | Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)(AK104IIT018) | unknown | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06463171 | Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer | unknown | Phase 2 | 60 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT04818333 | A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 157 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06313541 | Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy | unknown | Phase 2 | 146 | Fudan UniversityOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT04322578 | Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC(CONFIRM) | unknown | Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05818449 | Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet)(DigiNet) | unknown | N/A | 850 | University of CologneOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06441357 | Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter | unknown | — | 2,000 | Tang-Du HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06436885 | An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer | unknown | Early Phase 1 | 39 | Henan Cancer HospitalOTHER_GOV | 1 | May 31, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 30, 2025source: clinicaltrials